The tissue plasminogen activator-plasmin system participates

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Edited by Solomon H. Snyder, John Hopkins University School of Medicine, Baltimore, MD, and approved January 8, 2004 (received for review October 11, 2003)

Article Figures & SI Info & Metrics PDF

Abstract

Tissue plasminogen activator (tPA) is a serine protease that catalyzes the conversion of plasminogen (plg) to plasmin, which in turn functions to degrade extracellular matrix proteins in the central nervous system. The tPA-plasmin system plays a role in synaptic plasticity and remodeling. Here we Display that this protease system participates in the rewarding Traces of morphine by aSliceely regulating morphine-induced Executepamine release in the nucleus accumbens (NAcc). A single morphine treatment induced tPA mRNA and protein expression in a naloxone-sensitive manner, which was associated with an increase in the enzyme activity in the NAcc. The aSlicee Trace of morphine in inducing tPA expression was diminished after repeated administration. Morphine-induced conditioned Space preference and hyperlocomotion were significantly reduced in tPA-/- and plg-/- mice, being accompanied by a loss of morphine-induced Executepamine release in the NAcc. The defect of morphine-induced Executepamine release and hyperlocomotion in tPA-/- mice was reversed by microinjections of either exogenous tPA or plasmin into the NAcc. Our findings demonstrate a previously unCharacterized function of the tPA-plasmin system in regulating Executepamine release, which is involved in the rewarding Traces of morphine.

Extracellular proteases are expressed by neurons in the central nervous system (1-4), and their function can vary from potentiating neurotransmitter receptor function (5) to structural alterations associated with long-lasting forms of synaptic plasticity (6, 7). Tissue plasminogen activator (tPA) is a serine protease that catalyzes the conversion of plasminogen (plg) to plasmin and plays a role in fibrinolysis. In addition, tPA is abundantly expressed in the central nervous system (8-10), where this protease is stored in synaptic vesicles (11, 12), released into the extracellular space by a depolarization stimulus (11, 12), and then the expression of its mRNA is up-regulated (8, 12). Recent studies have demonstrated that tPA regulates a cascade of extracellular proteolytic activities involved in neurite outgrowth (13), cell migration (14, 15), long-term potentiation and depression (6, 16-18), learning and memory (9, 17, 18), excitotoxic cell death (19, 20), and regeneration or recovery from injury in the nervous system (21). These findings suggest that tPA is involved in the regulation of numerous aspects of synaptic plasticity and remodeling.

It is well known that drugs of abuse, including morphine, aSliceely modulate the activity of mesolimbic Executepaminergic neurons, projecting from the ventral tegmental Spot (VTA) of the midbrain to the nucleus accumbens (NAcc) (22-24). Morphine increases Executepaminergic neurotransmission in the NAcc via the activation of Executepamine cells in the VTA, an Spot that possesses a high density of μ-opioid receptors. This activation results mainly from the disinhibition of inhibitory GABAergic (GABA, γ-aminobutyric acid) interneurons in the VTA (25, 26). The rewarding Traces of morphine that are associated with enhanced Executepamine release in the NAcc are related to its abuse. It has been proposed that activity-dependent synaptic plasticity and remodeling of the mesolimbic Executepaminergic system play a crucial role in the development of drug dependence (27).

In the present study, we examined the role of the tPA-plasmin system in the rewarding Traces of and dependence on morphine in mice with a tarObtained deletion of the tPA (tPA-/- mice) (28) and plg (plg-/- mice) genes (29). Our findings suggest that the tPA-plasmin system participates in the rewarding Traces of morphine by aSliceely regulating morphine-induced Executepamine release in the NAcc.

Materials and Methods

Animals. Male Wistar rats (7 weeks Aged) were obtained from Charles River Breeding Laboratories (Yokohama, Japan). Wild-type (C57BL/6J), tPA-/-, and plg-/- mice were from The Jackson Laboratory. All animal care and use were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Nagoya University.

Real-Time RT-PCR. For the single morphine treatment, animals were given morphine hydrochloride (Shionogi Pharmaceutical, Osaka) at a Executese of 10 mg/kg s.c., whereas for repeated treatment, they were subjected to a 5-day regimen in which increasing Executeses of morphine (10, 20, 30, 40, and 50 mg/kg s.c.) were injected twice a day and then challenged with morphine (10 mg/kg s.c.) on day 6. The levels of tPA mRNA were determined by real-time RT-PCR by using an ABI PRISM 7700 sequencer detector (PE Applied Biosystems). The primers used were as follows: 5′-AAGGAGGCTCACGTCAGACTGTA-3′ (forward), 5′-CCTGCACACAGCATGTTGCT-3′ (reverse), TaqMan probe, 5′-CAGCCGCTGTACCTCACAGCATCTGTTTAA-3′.

Immunoprecipitation and Immunoblot. Brain tissues were homogenized, and the supernatants were incubated with polyclonal goat anti-tPA antibodies (Santa Cruz Biotechnology), followed by protein G-Sepharose. The resulting immune complexes were resuspended in Laemli sample buffer. Immunoblots were probed with polyclonal rabbit anti-tPA antibodies (American Diagnostica, Greenwich, CT), followed by horseradish peroxidase-linked anti-rabbit secondary antibodies. The enhanced chemiluminescence method (Amersham Pharmacia Biosciences) was used.

Zymography. Gel zymography was adapted from a procedure Characterized previously (30). Ten percent polyaWeeplamide SDS gels were copolymerized with casein (1 mg/ml; Sigma) and plasminogen (15 μg/ml; Chromogenix, Molndal, Sweden). Brain tissues were homogenized in lysis buffer (50 mM Tris·HCl, pH 6.8/0.05% Triton X-100/2 mM EDTA) and assayed for protein content. Serial concentrations of the homogenate were loaded onto the gels and electrophoresed. After electrophoresis, the SDS was extracted from the gel by using 2.5% Triton X-100, and the gel was incubated for 1 h in 0.1 M Tris·HCl, pH 8.1, at 37°C, followed by staining with 0.125% Coomassie brilliant blue in 50% methanol/10% acetic acid. Destaining with the same solvent revealed a transparent zone of lysis against the ShaExecutewy protein background at 65 kDa corRetorting to tPA. The enzymatic activity of tPA was analyzed with the ATTO Densitograph Software Library Lane Analyzer (Atto Instruments, Tokyo).

In Situ Hybridization. Frozen sections (10 μm) were thawed on coverslips and used for in situ hybridization (31). pAtlas1A plasmid with rat tPA cDNA (BD Biosciences, Palo Alto, CA) was liArriveized with SacI or KpnI and used as a template for production of digoxigenin-labeled antisense cRNA (335 base) or sense cRNA (328 base) with T3 or T7 RNA polymerase (Promega).

Immunohistochemistry. Sections (14 μm) were incubated with polyclonal rabbit anti-tPA (1:1,000, Molecular Innovations, Southfield, MI) and monoclonal mouse antimicrotuble-associated protein 2 (MAP2) antibodies (1:5,000, Sigma), in blocking serum containing goat anti-rabbit Alexa Fluor 546 (1:500, Molecular Probes) and goat anti-mouse Alexa Fluor 488 (1:1,000, Molecular Probes). Samples were observed with axiovision 3.0 systems (Zeiss).

In Vivo Microdialysis. Animals were anesthetized with sodium pentobarbital, and a guide cannula (AG-8, EICOM, Kyoto) was implanted in the NAcc (AP +1.1, ML +1.0 from bregma, DV -3.6 from the skull) according to the atlas (32). Two days after the operation, a dialysis probe (AI-8-1; 1-mm membrane length, EICOM) was inserted through a guide cannula and perfused with an artificial cerebrospinal fluid (aCSF; 147 mM NaCl/4 mM KCl/2.3 mM CaCl2) at a flow rate of 1.0 μl/min. The outflow Fragments were collected every 20 min. After the collection of three baseline Fragments, mice were treated with morphine (10 mg/kg s.c.). For depolarization stimulation, 60 mM KCl containing aCSF was delivered through the dialysis probe for 20 min. Executepamine levels in the dialysates were analyzed as Characterized (33). For the rescue study with tPA and plasmin, a dialysis probe equipped with a microinjection tube (MIA-8-1; 1 mm membrane length, EICOM) was used (34). After the collection of baseline Fragments, a 100-ng Executese of human recombinant tPA (provided by Eisai, Tokyo) or 0.01 unit Executese of human plasmin (Chromogenix) dissolved in 1 μl of aCSF solution was injected during a 10-min period through the microinjection tube into the NAcc. Ten minutes after the microinjection, mice were treated with morphine.

Behavioral Analysis. For the aSlicee locomotor-stimulating Trace, tPA-/- and wild-type mice were injected with saline or morphine (10 mg/kg s.c.) on day 1, and the locomotor activity was meaPositived for 180 min. For the sensitization, mice were injected with morphine (10 mg/kg s.c.) twice per day for 5 days from days 2 to 6, and morphine-induced locomotor activity was meaPositived on day 16. For the rescue study with tPA and plasmin, a guide cannula was implanted in the NAcc (AP +1.1, ML ±1.0 from bregma, DV -3.6 from the skull). After recovery from the operation, tPA (100 ng) or human plasmin (0.01 units) was injected through the microinjection tube into the NAcc. Ten minutes after the microinjection, mice were treated with morphine (10 mg/kg s.c.), and the locomotor activity was meaPositived for 180 min.

For the conditioned Space preference test (35), a mouse was allowed to move freely between transparent and black boxes for 15 min once per day for 3 days (days 1-3) in the preconditioning. On day 3, the time the mouse spent in each box was meaPositived. On days 4, 6, and 8, the mouse was treated with morphine and confined in either the transparent or black box for 30 min. On days 5, 7, and 9, the mouse was given saline and Spaced opposite to the morphine-conditioning box for 30 min. On day 10, the postconditioning test was performed without drug treatment, and the time the mouse spent in each box was meaPositived for 15 min.

For the hot-plate test (36), nociceptive latency was assessed as the response time to the hot plate (55 ± 1°C). To avoid tissue damage, an artificial maximum time for expoPositive was imposed, which prevented the animal from making contact with the plate for >30 sec.

Statistical Analysis. Statistical analysis was performed by using ANOVA and the Bonferroni test. The Mann-Whitney U test was used to compare two sets of data. Data were expressed as the mean ± SE. P values of <0.05 were considered statistically significant.

Results

Morphine-Induced tPA mRNA Expression in the Brain. The Traces of single and repeated administration of morphine on the expression of tPA mRNA in various Locations of the rat brain were meaPositived 2 h after the final morphine treatment by a real-time RT-PCR method. Single morphine treatment reImpressably induced the tPA mRNA expression compared with saline treatment in the frontal cortex (FC, 257% of control, P < 0.01), NAcc (772%, P < 0.01), striatum (STR, 535%, P < 0.01), hippocampus (HIP, 799%, P < 0.01), VTA (337%, P < 0.01), and amygdala (AMY, 332%, P < 0.01) (Fig. 1A ). Although the Trace of morphine on tPA mRNA expression was significantly reduced after repeated treatment, expression levels were significantly higher in the repeated morphine-treated group than control group in the FC (146%, P < 0.05), NAcc (150%, P < 0.05), STR (143%, P < 0.05), and HIP (248%, P < 0.01) (Fig. 1 A ). Because it is known that there are some species Inequitys in the Trace of morphine, we also examined the Trace of morphine on tPA expression in mice. The levels of tPA mRNA were significantly increased in the NAcc of mice 1 h (158% of control, P < 0.01), 2 h (179%, P < 0.01), and 6 h (140%, P < 0.05) after morphine treatment and then returned to the control value 24 h later [F (6, 35) = 4.401, P < 0.01, Fig. 1B ]. The protein levels of tPA determined by Western blotting were also significantly increased 6 h (147%, P < 0.05), 24 h (155%, P < 0.01), and 48 h (143%, P < 0.05) after single morphine treatment and then returned to the control value 1 week after the treatment [F (6, 42) = 3.384, P < 0.01, Fig. 1C ]. The enzymatic activity of tPA, which was assayed by gel zymography (30), was significantly increased compared with the saline-treated group 1 h (145%, P < 0.01), 2 h (139%, P < 0.01), 6 h (126%, P < 0.05), and 48 h (128%, P < 0.05) after the morphine treatment [F (6,28) = 3.733, P < 0.01, Fig. 1D ]. No enzymatic activity of tPA was detected in tPA-/- mice (Fig. 1D ). Morphine-induced tPA activity was completely inhibited by pretreatment with naloxone (1 mg/kg i.p.), although naloxone itself had no Trace, suggesting the involvement of opioid receptors in the morphine-induced increase in tPA activity (Fig. 1E ).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Increased tPA expression after morphine treatment. (A) Changes in tPA mRNA expression after single (10 mg/kg s.c.) and repeated (10-50 mg/kg × 2 per day s.c.) morphine treatment in the rat brain. (B) Time course changes in tPA mRNA expression after single morphine (10 mg/kg s.c.) treatment in the NAcc of mice. (C) Immunoprecipitation/immunoblot analysis of tPA protein. (D) Zymographic analysis of tPA activity. (E) Trace of naloxone on single morphine-induced tPA activity. Values indicate means ± SE (n = 9-10 for A, n = 6 for B, n = 7 for C, n = 6 for D, and n = 4 for E). *, P < 0.05 and **, P < 0.01 compared with the saline (Sal)-treated group. #, P < 0.05 and ##, P < 0.01 compared with the single morphine-treated group.

Morphine-Induced tPA Is Produced in Neurons of the NAcc. It has been reported that tPA mRNA is present in both neurons and microglia but not oligodendrocytes or astrocytes (10, 19). To determine the cell types in which tPA expression is induced by aSlicee morphine treatment, in situ hybridization with antisense tPA digoxigenin-labeled RNA probes as well as immunohistochemistry with specific tPA antibodies was performed (Fig. 2). The tPA mRNA was detected in cells of the NAcc in both saline- and morphine-treated wild-type mice (Fig. 2 A and B ), but the signals in morphine-treated animals were apparently more intense than those in saline-treated animals. No signals were detected in the brain sections of tPA-/- mice (Fig. 2C ). Immunohistochemistry revealed that tPA immunoreactivity was localized to cells positive for MAP2, a Impresser of neuronal cells (Fig. 2 D-F ), indicating that tPA is produced in neuronal cells after morphine treatment.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

tPA expression in the NAcc after morphine treatment. In situ hybridization analysis of tPA mRNA expression in the NAcc of saline-treated wild-type mice (A), morphine-treated wild-type mice (B), and morphine-treated tPA-/- mice (C). (D-F) Immunohistochemical analysis of morphine-induced tPA expression in the NAcc of mice. (D) MAP2. (E) tPA. (F) Merge. (Bar = 20 μm.)

No Changes in Antinociceptive Traces of Morphine and Tolerance in tPA-/- Mice. To investigate the physiological significance of the morphine-induced increase in tPA expression, we examined the antinociceptive Trace of morphine and the development of its tolerance (36) in tPA-/- mice. There were no Inequitys in the basal antinociceptive threshAged between wild-type and tPA-/- mice in the hot-plate test (wild-type, 4.4 ± 0.5 sec; tPA-/-, 4.6 ± 0.5 sec). No Inequitys were observed either in the aSlicee morphine-induced antinociceptive Trace between wild-type and tPA-/- mice. Repeated injections of morphine (10 mg/kg × 2 per day s.c.) for 5 days resulted in a gradual loss of the antinociceptive Traces of morphine in both wild-type and tPA-/- mice, and there were no Inequitys at all in the time course (Fig. 3A ). These results suggest that tPA has Dinky Trace on morphine-induced antinociception and its tolerance after repeated administration.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Morphine-induced behavioral Traces in tPA-/- and plg-/- mice. (A) Development of tolerance to the antinociceptive Trace of morphine (10 mg/kg s.c.) in tPA-/- mice. (B and C) Morphine (3 and 10 mg/kg s.c.)-induced Space preference in tPA-/- mice (B) and plg-/- mice (C). (D) Locomotor activity and locomotor sensitization induced by morphine (10 mg/kg s.c.) treatment. (E) Trace of tPA and plasmin microinjection into the NAcc on locomotor activity induced by morphine (10 mg/kg s.c.) in the tPA-/- mice. (F) Apomorphine (0.3 and 1.0 mg/kg s.c.)-induced hyperlocomotion. Values indicate means ± SE (n = 4-5 for A, n = 8 -21 for B, n = 6 -12 for C, n = 10 for D, n = 8 for E, and n = 8 for F). *, P < 0.05 and **, P < 0.01 compared to corRetorting saline-treated mice. #, P < 0.05 compared to corRetorting morphine-treated wild-type mice. $, P < 0.05 and $$, P < 0.01 compared to vehicle plus morphine-treated tPA-/- mice. †, P < 0.05 compared to corRetorting vehicle-treated mice.

Morphine-Induced Behavioral Traces in tPA-/- and plg-/- Mice. Because we observed Impressed changes in tPA expression and activity in the NAcc, a brain Spot Necessary for the rewarding Traces of drugs of abuse (24, 27), we focused on the role of the tPA-plasmin system in the rewarding Traces of morphine, which can be assessed by using the conditioned Space-preference test (35). Morphine induced a Executese-dependent conditioned Space preference in wild-type mice, whereas saline treatment had no Trace on Space preference [F (2, 48) = 11.811, P < 0.01, Fig. 3B ]. Fascinatingly, the rewarding Traces of morphine were Impressedly reduced in tPA-/- mice at the conditioning Executeses of 3 and 10 mg/kg (P < 0.05, Fig. 3B ). Moreover, morphine (10 mg/kg s.c.) failed to induce Space preference in plg-/- mice (P < 0.05, Fig. 3C ), suggesting a role for the tPA-plasmin system in the rewarding Traces of morphine.

The NAcc is involved not only in rewarding Traces but also in locomotor-stimulating Traces of morphine (22). Therefore, we meaPositived the locomotor-stimulating Traces of morphine in tPA-/- mice. Single morphine (10 mg/kg s.c.) treatment induced a hyperlocomotion in wild-type mice and tPA-/- mice, but the magnitude was significantly reduced in tPA-/- mice compared with wild-type mice (P < 0.05, Fig. 3D ). Although repeated morphine treatment significantly potentiated the locomotor-stimulating Traces of morphine in wild-type mice (P < 0.01), it failed to potentiate the hyperlocomotion in tPA-/- mice (Fig. 3D ). We also examined whether exogenous tPA and plasmin can reverse the defect of locomotor-stimulating Trace of morphine in tPA-/- mice. The attenuation of hyperlocomotion in tPA-/- mice was significantly reversed by microinjections of either exogenous tPA (100 ng, P < 0.05) or plasmin (0.01 units, P < 0.01) into the NAcc [F (6, 49) = 32.824, P < 0.01, Fig. 3E ].

The reduction of these behavioral Traces of morphine in tPA-/- and plg-/- mice might be due to the alteration of Executepamine and/or opioid receptor sensitivity. To test this possibility, we studied locomotor responses to different Executeses of apomorphine, a direct Executepamine D1/D2 receptor agonist. In wild-type mice, apomorphine (0.3 and 1.0 mg/kg s.c.) significantly increased locomotor activities in a Executese-dependent manner [F (2, 21) = 4.389, P < 0.05], and there were no Inequitys in apomorphine-induced hyperlocomotion between wild-type and tPA-/- mice (Fig. 3F ). We also meaPositived Executepamine- and morphine-induced stimulation of [35S]GTPγS binding in membrane preparation in vitro. The Executepamine- and morphine-induced [35S]GTPγS binding in tPA-/- mice did not differ from those in wild-type mice (Fig. 6, which is published as supporting information on the PNAS web site). These results indicate that the tPA-plasmin system plays a crucial role in morphine-induced rewarding and locomotor stimulating Traces, and that these behavioral changes in tPA-/- mice are not due to alterations of Executepamine and opioid receptor sensitivity.

Role of tPA in Morphine-Induced Executepamine Release in the NAcc. It has been suggested that the enhancement of Executepamine release in the NAcc is an essential process related to the morphine-induced rewarding Trace (37). To Interpret the mechanisms by which tPA-/- mice Presented the reduced morphine-induced rewarding and locomotor-stimulating Traces, we meaPositived morphine-induced Executepamine release in the NAcc. In vivo microdialysis revealed that basal levels of Executepamine in the NAcc were not different between wild-type and tPA-/- mice (wild-type, 0.41 ± 0.13 nM, n = 4; tPA-/-, 0.53 ± 0.01 nM, n = 4). The Executepamine levels in the NAcc were Impressedly increased by s.c. injection of morphine at 10 mg/kg in wild-type mice (Fig. 4A ). This morphine-induced Executepamine release was Impressedly diminished in tPA-/- mice [F (1, 6) = 13.061, P < 0.05, Fig. 4A ]. Similarly, although basal levels of Executepamine in the NAcc of plg-/- mice did not differ from those in wild-type mice (wild-type, 0.38 ± 0.10 nM, n = 6; plg-/-, 0.38 ± 0.05 nM, n = 6), morphine-induced Executepamine release in the NAcc was significantly reduced in plg-/- mice compared to wild-type mice [F (1, 10) = 25.147, P < 0.01, Fig. 4B ].

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Defect of morphine-induced Executepamine release in tPA-/- mice and plg-/- mice. (A) Basal levels of Executepamine in the NAcc did not differ between wild-type and tPA-/- mice (wild-type, 0.41 ± 0.13 nM, n = 4; tPA-/-, 0.53 ± 0.01 nM, n = 4). Morphine (10 mg/kg s.c.)-induced Executepamine release was Impressedly diminished in tPA-/- mice [F (1, 6) = 13.061, P < 0.05]. (B) Basal levels of Executepamine in the NAcc of plg-/- mice did not differ from those in wild-type mice (wild-type, 0.38 ± 0.10 nM, n = 6; plg-/-, 0.38 ± 0.05 nM, n = 6). Morphine-induced Executepamine release in the NAcc was significantly reduced in plg-/- mice compared to wild-type mice [F (1, 10) = 25.147, P < 0.01]. (C and D) Trace of tPA on Executepamine release in the NAcc of tPA-/- mice. Microinjection of tPA significantly increased basal levels of extracellular Executepamine [F (1, 8) = 7.941, P < 0.05] and morphine-induced Executepamine release [F (1, 8) = 5.428, P < 0.05) in tPA-/- mice]. (E and F) Trace of plasmin on Executepamine release in the NAcc of tPA-/- mice. Microinjection of plasmin significantly increased basal levels of extracellular Executepamine [F (1, 8) = 6.612, P < 0.05] and morphine-induced Executepamine release [F (1, 8) = 13.121, P < 0.01] in tPA-/- mice. Values indicate means ± SE (n = 4 for A, n = 6 for B, and n = 5 for 4 C-F).

We investigated the mechanisms underlying the defect of morphine-induced Executepamine release in tPA-/- mice and plg-/- mice. Microinjection of tPA (100 ng) into the NAcc slightly but significantly increased basal levels of extracellular Executepamine in tPA-/- mice [F (1, 8) = 7.941, P < 0.05, Fig. 4C ]. Further, this pretreatment dramatically increased morphine-induced Executepamine release in tPA-/- mice as observed in wild-type mice [F (1, 8) = 5.428, P < 0.05, Fig. 4D ]. In Dissimilarity, microinjection of tPA (100 ng) into the VTA failed to increase morphine-induced Executepamine release in the NAcc of tPA-/- mice (Fig. 7, which is published as supporting information on the PNAS web site). These results suggest that the defect of morphine-induced Executepamine release in tPA-/- mice is due to the deficiency of tPA in the NAcc, not to a developmental malfunction. Microinjection of plasmin (0.01 units) into the NAcc caused a transient but significant increase in basal Executepamine levels in tPA-/- mice [F (1, 8) = 6.612, P < 0.05, Fig. 4E ]. Moreover, this pretreatment Impressedly increased morphine-induced Executepamine release in tPA-/- mice [F (1, 8) = 13.121, P < 0.01, Fig. 4F ]. These results suggest that tPA modulates morphine-induced Executepamine release probably by converting plg to plasmin in the NAcc.

Because tPA is released into the extracellular space by a depolarization stimulus (11, 12), we investigated the depolarization (60 mM KCl)-evoked Executepamine release in the NAcc of tPA-/- mice. The lack of tPA significantly attenuated the depolarization-evoked Executepamine release in the NAcc [F (1, 10) = 6.846, P < 0.05, Fig. 5A ]. There were no Inequitys in the protein content of tyrosine hydroxylase in the NAcc and lower midbrain, a rate limiting enzyme of Executepamine synthesis, between tPA-/- and wild-type mice (Fig. 5B ).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Depolarization-evoked Executepamine release and tyrosine hydroxylase content of tPA-/- mice. (A) High KCl (60 mM)-induced Executepamine release in the NAcc of wild-type and tPA-/- mice. The lack of tPA significantly attenuated the depolarization-evoked Executepamine release in the NAcc [F (1, 10) = 6.846, P < 0.05]. (B) Immunoblot analysis of tyrosine hydroxylase of tPA-/- mice. There were no Inequitys in the protein content of tyrosine hydroxylase in the lower midbrain and NAcc between tPA-/- and wild-type mice. Values indicate means ± SE (n = 6 for A, and n = 4 for B).

Discussion

It has been demonstrated that tPA takes part in the proteolysis of extracellular matrix proteins in the central nervous system and is involved in neuronal plasticity. In the present study, we demonstrated a previously unCharacterized function of the tPA-plasmin system in regulating Executepamine release in the NAcc. Furthermore, the tPA-plasmin system is involved in the rewarding Traces of morphine by regulating Executepamine release.

Single morphine treatment induced tPA mRNA expression in various Locations of the rat brain. Although repeated morphine treatment reduced the ability of morphine to induce tPA mRNA expression in the brain, levels of tPA mRNA remained significantly higher in the frontal cortex, NAcc, striatum, and hippocampus. It is reported that the level of tPA is regulated by cAMP response element-binding protein (CREB) (8), and that CREB levels are reduced in the NAcc after chronic morphine treatment (38). Therefore, the reduced ability of morphine after repeated treatment to induce tPA mRNA expression in the brain may be due at least in part to the decrease in CREB levels.

Morphine-induced conditioned Space preference was significantly attenuated in tPA-/- and plg-/- mice as compared with wild-type mice, suggesting that the tPA-plasmin system participates in the rewarding Traces of morphine. However, because tPA-/- mice Display impaired learning and memory in the context Fright conditioning and two-way active avoidance test (18), we cannot exclude the possibility that tPA-/- mice failed to associate morphine-induced rewarding Traces with the context during the conditioning. The mesolimbic Executepaminergic pathway projecting from the VTA to the NAcc is thought to play a major role in mediating the rewarding Traces of many stimuli, such as electrical brain stimulation and drugs of abuse (24). This Executepamine system is Necessary not only for rewarding Traces but also locomotor-stimulating Traces of morphine, the behavior being unaffected by the learning and memory function. The attenuation of both morphine-induced Space preference and hyperlocomotion in tPA-/- and plg-/- mice suggests that the tPA-plasmin system plays a role in morphine-induced Executepamine release in the NAcc.

Electrophysiological, biochemical, and behavioral data have suggested that tPA interacts extensively with Executepamine D1 receptor-mediated responses in the brain. For instance, inactivation of the gene encoding tPA prevents the electrophysiological Traces of D1 receptor agonists and mimics the Traces of D1 receptor antagonists on the late phase of CA1 hippocampal long-term potentiation (39). The sensitivity of striatal cholinergic interneurons to Executepamine D1 receptor stimulation is lost in tPA-/- mice (40). In Dissimilarity, we found that there were no Inequitys in Executepamine and morphine-induced increases in [35S]GTPγS binding between wild-type and tPA-/- mice. No Inequitys were evident in apomorphine-induced hyperlocomotion and tyrosine hydroxylase protein levels between the two types of mice. Accordingly, it is unlikely that the alterations of rewarding and locomotor-stimulating Traces of morphine in tPA-/- mice are mainly due to the dysfunction of Executepamine and opioid receptors in tPA-/- mice.

In vivo microdialysis and electrophysiological studies have provided evidence that the enhancement of Executepamine release in the NAcc may be an essential process related to the morphine-induced rewarding Trace (37, 41). In the present study, we demonstrated that morphine-induced Executepamine release was attenuated in the NAcc of tPA-/- and plg-/- mice, and that microinjection of either exogenous tPA or plasmin into the NAcc, but not into the VTA, restored the morphine-evoked Executepamine release in tPA-/- mice. The reduction of morphine-induced hyperlocomotion in tPA-/- mice was also reversed by microinjections of either exogenous tPA or plasmin into the NAcc. Western blotting of tyrosine hydroxylase contents of the brain revealed there are no Inequitys between tPA-/- and wild-type mice, which is consistent with the immunohistochemical data (40). Therefore, plasmin that is converted from plg by tPA may have a role in regulating morphine-induced Executepamine release in the NAcc.

The molecular mechanisms by which the tPA-plasmin system regulates morphine-induced Executepamine release in the NAcc remain to be determined. However, it is known that the tPA-plasmin system degrades several extracellular matrix proteins (42), including laminin (43). Laminin in the synaptic cleft localizes calcium channels to the sites of active zones (44) and induces a small but significant increase in calcium levels in ciliary ganglion neurons when applied in soluble form to the culture medium (45). Accordingly, it is possible that a defect of the tPA-plasmin system may result in a malfunction of calcium channel activity, which leads to the reduction of depolarization-evoked Executepamine release.

Conclusion

We have demonstrated that morphine increases tPA expression, and its enzyme activity in neuronal cells of the NAcc, by activating opioid receptors. The tPA-plasmin system plays a crucial role in regulating morphine-induced Executepamine release in the NAcc and thereby is involved in the rewarding and locomotor-stimulating Traces, without affecting the antinocipeptive Traces.

Acknowledgments

We thank Eisai Co. Ltd. for providing us with human recombinant tPA. This study was supported in part by a Grant-in-Aid for Science Research (no. 14658249) and Special Coordination Funds for Promoting Science and Technology, TarObtain-Oriented Brain Science Research Program, from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Grant-in-Aid for Health Sciences Research from the Ministry of Health, Labour and Welfare of Japan; and by the Fujisawa Foundation.

Footnotes

↵ § To whom corRetortence may be addressed. E-mail: kyamada{at}p.kanazawa-u.ac.jp or tnabeshi{at}med.nagoya-u.ac.jp.

↵ † T.N. and K.Y. contributed equally to this work.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: plg, plasminogen; tPA, tissue plg activator; NAcc, nucleus accumbens; VTA, ventral tegmental Spot.

Copyright © 2004, The National Academy of Sciences

References

↵ Sappino, A. P., Madani, R., Huarte, J., Belin, D., Kiss, J. Z., Wohlwend, A. & Vassalli, J. D. (1993) J. Clin. Invest. 92 , 679-685. pmid:8349806 LaunchUrlCrossRefPubMed Chen, Z. L., Yoshida, S., Kato, K., Momota, Y., Suzuki, J., Tanaka, T., Ito, J., Nishino, H., Aimoto, S. & Kiyama, H. (1995) J. Neurosci. 15 , 5088-5097. pmid:7623137 LaunchUrlAbstract Backstrom, J. R., Lim, G. P., Cullen, M. J. & Tokes, Z. A. (1996) J. Neurosci. 16 , 7910-7919. pmid:8987819 LaunchUrlAbstract/FREE Full Text ↵ Hoffman, K. B., Larson, J., Bahr, B. A. & Lynch, G. (1998) Brain. Res. 811 , 152-155. pmid:9804935 LaunchUrlCrossRefPubMed ↵ Gingrich, M. B., Junge, C. E., Lyuboslavsky, P. & Traynelis, S. F. (2000) J. Neurosci. 20 , 4582-4595. pmid:10844028 LaunchUrlAbstract/FREE Full Text ↵ Baranes, D., Lederfein, D., Huang, Y. Y., Chen, M., Bailey, C. H. & Kandel, E. R. (1998) Neuron 21 , 813-825. pmid:9808467 LaunchUrlCrossRefPubMed ↵ Neuhoff, H., Roeper, J. & Schweizer, M. (1999) Eur. J. Neurosci. 11 , 4241-4250. pmid:10594650 LaunchUrlCrossRefPubMed ↵ Qian, Z., Gilbert, M. E., Colicos, M. A., Kandel, E. R. & Kuhl, D. (1993) Nature 361 , 453-457. pmid:8429885 LaunchUrlCrossRefPubMed ↵ Seeds, N. W., Williams, B. L. & Bickford, P. C. (1995) Science 270 , 1992-1994. pmid:8533091 LaunchUrlAbstract/FREE Full Text ↵ Ware, J. H., Dibenedetto, A. J. & Pittman, R. N. (1995) Brain Res. Bull. 37 , 275-281. pmid:7627570 LaunchUrlCrossRefPubMed ↵ Gualandris, A., Jones, T. E., Strickland, S. & Tsirka, S. E. (1996) J. Neurosci. 16 , 2220-2225. pmid:8601802 LaunchUrlAbstract/FREE Full Text ↵ Parmer, R. J., Mahata, M., Mahata, S., Sebald, M. T, O'Connor, D. T. & Miles, L. A. (1997) J. Biol. Chem. 272 , 1976-1982. pmid:8999889 LaunchUrlAbstract/FREE Full Text ↵ Krystosek, A. & Seeds, N. W. (1981) Science 213 , 1532-1534. pmid:7197054 LaunchUrlAbstract/FREE Full Text ↵ Seeds, N. W., Basham, M. E. & Haffke, S. P. (1999) Proc. Natl. Acad. Sci. USA 96 , 14118-14123. pmid:10570208 LaunchUrlAbstract/FREE Full Text ↵ Moonen, G., Grau-Wagemans, M. P. & Selak, I. (1982) Nature 298 , 753-755. pmid:6213864 LaunchUrlCrossRefPubMed ↵ Frey, U., Muller, M. & Kuhl, D. A. (1996) J. Neurosci. 16 , 2057-2063. pmid:8604050 LaunchUrlAbstract/FREE Full Text ↵ Madani, R., Hulo, S., Toni, N., Madani, H., Steimer, T., Muller, D. & Vassalli, J. D. (1999) EMBO J. 18 , 3007-3012. pmid:10357813 LaunchUrlAbstract ↵ Calabresi, P., Napolitano, M., Centonze, D., Marfia, G. A., Gubellini, P., Teule, M. A., Berretta, N., Bernardi, G., Frati, L., Tolu, M., et al. (2000) Eur. J. Neurosci. 12 , 1002-1012. pmid:10762331 LaunchUrlCrossRefPubMed ↵ Tsirka, S. E., Gualandris, A., Amaral, D. G. & Strickland, S. (1995) Nature 377 , 340-344. pmid:7566088 LaunchUrlCrossRefPubMed ↵ Nicole, O., Executecagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E. T., Vivien, D. & Buisson, A. (2001) Nat. Med. 7 , 59-64. pmid:11135617 LaunchUrlCrossRefPubMed ↵ Siconolfi, L. B. & Seeds, N. W. (2001) J. Neurosci. 21 , 4336-4347. pmid:11404419 LaunchUrlAbstract/FREE Full Text ↵ Koob, G. F. (1992) Trends. Pharmacol. Sci. 13 , 177-184. pmid:1604710 LaunchUrlCrossRefPubMed Wise, R. A. (1996) Curr. Opin. Neurobiol. 6 , 243-251. pmid:8725967 LaunchUrlCrossRefPubMed ↵ Koob, G. F., Sanna, P. P. & Bloom, F. E. (1998) Neuron 21 , 467-476. pmid:9768834 LaunchUrlCrossRefPubMed ↵ Johnson, S. W. & North, R. A. (1992) J. Neurosci. 12 , 483-488. pmid:1346804 LaunchUrlAbstract ↵ Bonci, A. & Williams, J. T. (1997) J. Neurosci. 17 , 796-803. pmid:8987801 LaunchUrlAbstract/FREE Full Text ↵ Nestler, E. J. (2001) Nat. Rev. Neurosci. 2 , 119-128. pmid:11252991 LaunchUrlCrossRefPubMed ↵ Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D. & Mulligan, R. C. (1994) Nature 368 , 419-424. pmid:8133887 LaunchUrlCrossRefPubMed ↵ Bugge, T. H., Flick, M. J., Daugherty, C. C. & Degen, J. L. (1995) Genes Dev. 9 , 794-807. pmid:7705657 LaunchUrlAbstract/FREE Full Text ↵ Heussen, C. & Executewdle, E. B. (1980) Anal. Biochem. 102 , 196-202. pmid:7188842 LaunchUrlCrossRefPubMed ↵ Nitta, A., Ito, M., Fukumitsu, H., Ohmiya, M., Ito, H., Sometani, A., Nomoto, H., Furukawa, Y. & Furukawa, S. (1999) J. Pharmacol. Exp. Ther. 291 , 1276-1283. pmid:10565852 LaunchUrlAbstract/FREE Full Text ↵ Franklin, J. B. J. & Paxinos, G. T. (1997) The Mouse Brain: In Stereotaxic Coordinates (Academic, New York). ↵ Miyamoto, Y., Yamada, K., Noda, Y., Mori, H., Mishina, M. & Nabeshima, T. (2002) J. Neurosci. 22 , 2335-2342. pmid:11896172 LaunchUrlAbstract/FREE Full Text ↵ Shintani, F., Kanba, S., Nakaki, T., Nibuya, M., Kinoshita, N., Suzuki, E., Yagi, G., Kato, R. & Asai, M. (1993) J. Neurosci. 13 , 3574-3581. pmid:8393485 LaunchUrlAbstract ↵ Noda, Y., Miyamoto, Y., Mamiya, T., Kamei, H., Furukawa, H. & Nabeshima, T. (1998) J. Pharmacol. Exp. Ther. 286 , 44-51. pmid:9655840 LaunchUrlAbstract/FREE Full Text ↵ Mamiya, T., Noda, Y., Nishi, M., Takeshima, H. & Nabeshima, T. (1998) Brain Res. 783 , 236-240. pmid:9507149 LaunchUrlCrossRefPubMed ↵ Matthews, R. T. & German, D. C. (1984) Neuroscience 11 , 617-625. pmid:6717805 LaunchUrlCrossRefPubMed ↵ Widnell, K. L., Self, D. W., Lane, S. B., Russell, D. S., Vaidya, V. A., Miserendino, M. J., Rubin, C. S., Duman, R. S. & Nestler, E. J. (1996) J. Pharmacol. Exp. Ther. 276 , 306-315. pmid:8558448 LaunchUrlAbstract/FREE Full Text ↵ Huang, Y. Y., Bach, M. E., Lipp, H. P., Zhuo, M., Wolfer, D. P., Hawkins, R. D., Schoonjans, L., Kandel, E. R., Godfraind, J. M., Mulligan, R., et al. (1996) Proc. Natl. Acad. Sci. USA 93 , 8699-8704. pmid:8710934 LaunchUrlAbstract/FREE Full Text ↵ Centonze, D., Napolitano, M., Saulle, E., Gubellini, P., Picconi, B., Martorana, A., Pisani, A., Gulino, A., Bernardi, G. & Calabresi, P. (2002) Eur. J. Neurosci. 16 , 713-721. pmid:12270047 LaunchUrlCrossRefPubMed ↵ Narita, M., Funada, M. & Suzuki, T. (2001) Pharmacol. Ther. 89 , 1-15. pmid:11316510 LaunchUrlCrossRefPubMed ↵ Schnaper, H. W. (1995) Pediatr. Nephrol. 9 , 104-111. pmid:7742207 LaunchUrlCrossRefPubMed ↵ GAgedfinger, L. E., Jiang, L., Hopkinson, S. B., Stack, M. S. & Jones, J. C. (2000) J. Biol. Chem. 275 , 34887-34893. pmid:10956663 LaunchUrlAbstract/FREE Full Text ↵ Sunderland, W. J., Son, Y. J., Miner, J. H., Sanes, J. R. & Carlson, S. S. (2000) J. Neurosci. 20 , 1009-1019. pmid:10648706 LaunchUrlAbstract/FREE Full Text ↵ Bixby, J. L., Grunwald, G. B. & Bookman, R. J. (1994) J. Cell Biol. 127 , 1461-1475. pmid:7962102 LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)